The 7 analysts offering 12-month price forecasts for Cara Therapeutics Inc have a median target of 35.00, with a high estimate of 47.00 and a low estimate of 21.00. The median estimate represents a +22.68% increase from the last price of 28.53.
The current consensus among 7 polled investment analysts is to Buy stock in Cara Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.58
Reporting Date May 06
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.